# DESCRIPTION

## TECHNICAL FIELD

- define technical field

## BACKGROUND

- introduce IL13 receptor
- describe expression in normal tissue
- describe expression in cancer cells
- limitations of IL13-ligand based CAR
- previous work on IL13 mutants

## SUMMARY

- describe IL13Rα2 targeted CAR
- introduce variant IL13 CAR
- describe nucleic acid molecule encoding CAR
- describe expression vector comprising nucleic acid molecule
- describe viral vector comprising nucleic acid molecule
- describe population of human T cells containing nucleic acid molecule
- describe population of human T cells containing expression vector or viral vector
- describe method of treating cancer
- describe administering CAR T cells
- describe method of preparing CAR T cells
- describe T cells harboring vector expressing variant IL13 CAR
- describe CAR comprising variant IL13 domain
- describe spacer region
- describe transmembrane domain
- describe costimulatory domain
- describe CD3ζ signaling domain
- describe truncated EGFR and truncated CD19
- describe amino acid modification
- describe conservative substitution
- describe non-conservative substitution
- describe grouping of amino acids
- describe producing CAR using vector
- describe T2A ribosome skip sequence
- describe truncated EGFR or CD19
- describe controlling proliferation
- describe ablation of CAR+ T cells
- describe producing CAR using recombinant DNA techniques
- describe assembling coding sequence
- describe inserting coding region into expression vector
- describe transforming expression host cell line
- describe transducing T cell subsets
- describe isolating central memory T cells
- describe activating and transducing T cells
- describe expanding and cryopreserving T cells
- describe additional methods of preparing CAR T cells
- describe incorporating references
- describe features and advantages of the invention

## DETAILED DESCRIPTION

- describe CAR T cells with IL13Rα2 targeting
- detail potent antigen-dependent cytotoxicity
- describe in vivo delivery and tumor model results
- define IL13Rα2 targeted CAR structure
- specify amino acid sequences for IL13 variant CAR
- describe signal sequence options
- detail additional sequences for monitoring expression
- specify codon optimization for human cell expression
- introduce spacer region options
- describe human Fc region and hinge portion spacers
- detail IgG4 Fc hinge and CH3 domain spacers
- specify linker/spacer region sequences
- describe transmembrane domain options
- introduce costimulatory domain options
- detail 4-1BB co-signaling domain sequence
- specify costimulatory domain modifications
- describe CD3ζ signaling domain sequence
- detail CD3ζ signaling domain modifications
- introduce truncated EGFR and CD19 sequences
- describe ribosomal skip sequence usage
- define amino acid modifications and substitutions
- describe CAR production using vectors and T2A skip sequence
- outline CAR expression and T cell transduction methods

### EXAMPLES

- introduce IL13 variants
- describe binding affinity of IL13 C4 and D7
- summarize surface plasmon resonance studies
- report binding affinity to IL13Rα2
- report binding affinity to IL13Rα1
- describe biological assays
- summarize phosphorylation of STAT6
- summarize upregulation of CCL26 gene
- summarize cell proliferation
- introduce CAR that include C4 IL13, D7 IL13, E12Y IL13 or WT IL13
- describe CAR design
- summarize flow cytometry analysis
- evaluate target specificity of IL13-CART cells
- summarize binding affinities to IL13Rα2
- summarize binding affinities to IL13Rα1
- assess IL13Rα2-targeting abilities
- evaluate antigen-specific T cell activation
- summarize CD107a expression
- summarize cytokine production
- perform in vitro tumor killing assays
- evaluate functional differences between IL13 wild type and variant CAR T cells
- perform in vivo anti-tumor efficacy evaluation
- evaluate tumor growth and survival
- perform Kaplan-Meier survival analysis
- evaluate in vivo anti-tumor activity
- display diminished effector activity against IL13Rα1-expressing tumors
- evaluate relative effector activity of IL13 wild type and variant CART cells
- perform long-term killing assays
- evaluate anti-tumor activity in xenograft models
- perform Winn assay
- describe methods used in examples
- clone IL-13 variants
- express and purify proteins
- biotinylate receptor expression
- quantify protein concentrations
- display IL-13 on yeast
- analyze fluorescence
- conduct surface plasmon resonance
- determine kinetic parameters
- perform TF-1 cell proliferation assays
- construct CAR sequences
- isolate enriched Tn/Mem cells
- describe CAR T cell therapy
- detail activation, lentiviral transduction, and ex vivo expansion of CAR T cells
- outline cytokine production assays
- describe cytotoxicity assays
- detail xenograft models
- explain statistical analysis
- cite references for gene expression profiling
- cite references for yeast surface display
- cite references for CAR T therapies
- cite references for IL-13-mediated regulation of learning and memory
- cite references for regression of glioblastoma after CAR T-cell therapy
- cite references for bioactivity and safety of IL13Ralpha2-redirected CAR CD8+ T cells
- cite references for stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas
- cite references for engineering antibody therapeutics
- cite references for molecular expression analysis of restrictive receptor for interleukin 13
- cite references for analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism
- cite references for chimeric antigen receptor-modified T cells for acute lymphoid leukemia
- cite references for dysregulation of the IL-13 receptor system
- cite references for structure-guided engineering of TGF-betas
- cite references for chimeric antigen receptors with mutated IgG4 Fc spacer
- cite references for specific recognition and killing of glioblastoma multiforme
- cite references for interleukin-13 receptor alpha2 chain
- cite references for suppression of human glioma xenografts
- cite references for T cells redirected to interleukin-13Ralpha2
- cite references for molecular basis for shared cytokine recognition
- cite references for chimeric antigen receptor T cells for sustained remissions in leukemia
- cite references for instructive roles for cytokine-receptor binding parameters
- cite references for interleukin-13 receptor alpha' but not alpha chain
- cite references for targeting IL13Ralpha2 activates STAT6-TP63 pathway

## OTHER EMBODIMENTS

- disclaim limitations

